Clinical trials: Psychoses, Substance Induced
Severe Mental Illness, Nicotine Dependence
Electronic Decision Support Systems for Smokers With Severe Mental Illness
This randomized clinical trial among SMI smokers assessed whether the EDSS with carbon monoxide monitor and health-checklist feedback lead to higher rates of initiation of smoking cessation treatment, days of smoking abstinence…
- Conditions
- Severe Mental Illness, Nicotine Dependence, Schizophrenia, Tobacco Use Disorder
- Trial name
- NCT01412866
- Testing
- EDSS with CO feedback and health checklist, EDSS with health checklist feedback alon
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Substance-Related Disorders, Mental Disorder
Community Health Worker Training to Reduce Depression and Substance Use Stigma in TB/HIV Care in South Africa
Poor engagement in care contributes to HIV- and TB-related morbidity and mortality in South Africa (SA). Community health workers (CHWs) are frontline lay health workers who work to re-engage patients who are lost to follow-up…
- Conditions
- Substance-Related Disorders, Mental Disorder, Social Stigma, Depression
- Trial name
- Siyakhana (NCT05282173)
- Testing
- Siyakhana CHW Training
- Where
- South Africa
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- University of Maryland, College Park
Tobacco Use, Tobacco Smoking
Persistence Targeted Smoking Cessation in Serious Mental Illness (SMI)
Due to the pandemic, this study was modified from a randomized clinical trial to test the feasibility, initial efficacy, and mechanisms of action of our PTSC-S intervention to a feasibility and acceptability test of our…
- Conditions
- Tobacco Use, Tobacco Smoking, Tobacco Use Cessation, Tobacco Use Disorder
- Trial name
- PTSC-S (NCT03873337)
- Testing
- Persistence Targeted Smoking Cessation in SMI (PTSC-S), Nicotine patch
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Rutgers, The State University of New Jersey
Smoking Cessation, Nicotine Addiction
Circuitry-Guided Smoking Cessation in Schizophrenia
In a double-blinded, randomized, parallel controlled design, patients with schizophrenia spectrum disorder will be exposed to active or sham repetitive transcranial magentic stimulation (TMS) which was guided by functional…
- Conditions
- Smoking Cessation, Nicotine Addiction, Schizophrenia
- Trial name
- NCT03281629
- Testing
- Active TMS stimulation
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Maryland, Baltimore
Alcohol Abuse, Schizophrenia
Contingency Management of Alcohol Abuse in the Severely Mentally ILL
The investigators will evaluate the efficacy of a comprehensive 12-week contingency management intervention for treating alcohol dependence for persons with severe mental illness who are seen within the context of a community…
- Conditions
- Alcohol Abuse, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- CMETG (NCT01567943)
- Testing
- Contingency Management
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- University of Washington
Schizophrenia, Alcohol Use Disorder
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
This double-blind, randomized study will evaluate the efficacy, safety and tolerability of ALKS 3831 in subjects with schizophrenia and alcohol use disorder (AUD).
- Trial name
- NCT02161718
- Testing
- Samidorphan + olanzapine (ALKS 3831)
- Where
- 71 sites in United States, Bulgaria and 1 more
- Volunteers
- 300 people
- Sponsor
- Alkermes, Inc.
Schizophrenia, Dual Diagnosis
Cannabis and Schizophrenia: Self-Medication and Agonist Treatment
The first aim of this study is to determine whether a brain reward center (BRC) deficiency in patients with schizophrenia (SCZ) and cannabis use disorder (CUD) will be normalized when patients are given cannabis or dronabinol.
- Conditions
- Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder
- Trial name
- NCT00946348
- Testing
- Dronabinol, Cannabis
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Tobacco Dependence, Schizophrenia
Cigarette Smoking in Smokers With and Without Schizophrenia
Higher rates and severity of tobacco dependence in people with schizophrenia, as compared with the general population, contribute to the lower life expectancy seen in this population.
- Trial name
- NCT04001114
- Testing
- Sampling Research Cigarettes
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes
Approximately 25% of people with schizophrenia abuse marijuana. These people may be using marijuana to self-medicate symptoms such as hallucinations (hearing or seeing things that are not heard or seen by others) or delusions…
- Trial name
- NCT01832766
- Testing
- Dronabinol
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Colorado, Denver
Bipolar Disorder, Schizophrenia
Novel Pharmacotherapy Approaches in Smokers With Serious Mental Illness
Approximately 60 chronic smokers with bipolar disorder, schizophrenia or schizoaffective disorder who are motivated to try to quit smoking will be randomized to receive smoking cessation treatment with the FDA-approved…
- Conditions
- Bipolar Disorder, Schizophrenia, Schizoaffective Disorder, Nicotine Dependence
- Trial name
- NCT04011280
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of California, San Diego
Cannabis Dependence, Marijuana Dependence
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
Cannabis use disorders are an important public health problem in the United States, but no effective pharmacotherapies are available to treat these disorders.
- Trial name
- DCCS (NCT01598896)
- Testing
- Dronabinol, Clonidine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mclean Hospital
Schizophrenia, Schizoaffective Disorder
Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder
The proposed study is a 4-site, 12-week, novel, feasibility, investigation of patients who have co-occurring diagnoses of schizophrenia and current substance use disorder (alcohol, cocaine, heroin, or cannabis).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Substance Use Disorders
- Trial name
- NCT03526354
- Testing
- Brexpiprazole, Treatment as Usual
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Massachusetts, Worcester
Schizophrenia, Psychotic Disorders
A Brief Community Linkage Intervention for Dually Diagnosed Individuals
Surveys suggest that up to 80% of veterans with a persistent mental illness have a co-occurring substance use disorder. Substance abuse among this population is problematic and often results in poor engagement in treatment and…
- Conditions
- Schizophrenia, Psychotic Disorders, Substance-Related Disorders, Bipolar Disorder
- Trial name
- TLC (NCT00137267)
- Testing
- Time limited case management, Health Education
- Where
- 2 sites in United States
- Volunteers
- 102 people
- Sponsor
- US Department of Veterans Affairs
Psychosis, Substance Use
Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) and Substance Use: A Pilot Study
The purpose of this study is to evaluate Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) for families experiencing early psychosis and substance use delivered exclusively or primarily via telehealth…
- Conditions
- Psychosis, Substance Use, Substance Use Disorders, Family
- Trial name
- NCT05380583
- Testing
- CRAFT-EP, TAU
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse), Infant Development
Maternal Adversity, Vulnerability and Neurodevelopment
Maternal Adversity Vulnerability and Neurodevelopment (MAVAN) project is a prospective community-based, pregnancy and birth cohort of Canadian mother-child dyads.
- Conditions
- Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse), Infant Development, Infant Behavior
- Trial name
- MAVAN (NCT03434457)
- Where
- Canada
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Schizophrenia, Dual Diagnosis
Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?
In this translational research proposal, based on our formulation, we seek to confirm and expand upon data obtained in our pilot study suggesting that cannabis and the cannabinoid agonist dronabinol, given in low dose to patients…
- Conditions
- Schizophrenia, Dual Diagnosis, Psychotic Disorder, Cannabis Use Disorder
- Trial name
- NCT01964404
- Testing
- Marijuana, Dronabinol
- Where
- 2 sites in United States
- Volunteers
- 263 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder
Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia
There is a high prevalence of smoking among people with schizophrenia, and there are few smoking treatment programs for these smokers.
- Trial name
- NCT00136760
- Testing
- Bupropion, non-contingent reinforcement plus bupropion
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Brown University
Schizophrenia, Psychotic Disorders
Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
The purpose of this study is to compare the efficacy of oral risperidone (Risperdal) to risperidone long-acting (Consta) in reducing alcohol use in persons diagnosed with schizophrenia or schizoaffective disorder.
- Conditions
- Schizophrenia, Psychotic Disorders, Substance Abuse, Alcohol Abuse
- Trial name
- NCT00130923
- Testing
- Risperidone Long Acting, oral risperidone
- Where
- 8 sites in United States
- Volunteers
- 95 people
- Sponsor
- Dartmouth-Hitchcock Medical Center